Actinium reports new data demonstrating effective lymphodepletion supporting Iomab-ACT
Actinium Pharmaceuticals announced data from its Iomab-ACT program. A series of preclinical studies demonstrated that targeting CD45 with an ARC or Antibody Radiation-Conjugate can achieve potent yet transient lymphodepletion in a safe and effective manner. February 21, 2019